How effective is mobosetinib/mobotinib against EGFR mutations?

Mobocertinib is a new targeted drug specifically designed to deal with rare but clinically highly challenging EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC). Traditional EGFR mutations, such as L858R or exon 19 deletion mutations, respond well to first-generation (such as gefitinib) or third-generation (such as osimertinib) EGFR-TKIs, but exon 20 insertion mutations usually have steric hindrance, making it difficult for traditional drugs to effectively bind to the receptor site, resulting in treatment failure. MobosetinibBy optimizing its molecular structure, it can highly selectively bind to mutant EGFR protein, thereby inhibiting signal transduction and inducing tumor cell apoptosis.

From the perspective of overseas practical applications, moboxetinib has shown a certain objective response rate and disease control rate in EGFR exon 20 insertion mutation-positive patients whose disease has progressed despite platinum-based chemotherapy, providing an optional systemic treatment option for this type of patients. Especially when no other targeted drugs are available, mobosetinib fills the gap in clinical treatment. Compared with amivantamab (Amivantamab), mobosetinib is more convenient as an oral medication and is conducive to long-term patient compliance management. Although the efficacy differs in different mutation subtypes and disease stages, the overall trend is that mobosetinib can significantly improve PFS (progression-free survival) and extend OS (overall survival) in some patients, which is more advantageous than chemotherapy or non-specific treatment.

It should be pointed out in particular that due to the heterogeneity of EGFR exon 20 insertion mutations, the clinical effect of moboxetinib is closely related to the type of mutation site, baseline pathological status and individual patient differences. Therefore, it is recommended to conduct high-precision genetic testing before use to clarify the type of mutation, and to work with a specialist to develop a personalized medication plan to ensure maximum benefit from treatment.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib